Literature DB >> 11068972

Distress and psychiatric morbidity among women from high-risk breast and ovarian cancer families.

J C Coyne1, N R Benazon, C G Gaba, K Calzone, B L Weber.   

Abstract

This study assessed psychological distress and psychiatric disorder in high-risk women enrolled in a hereditary breast and ovarian cancer registry, and it evaluated the concordance between self-report data and interview-based psychiatric diagnosis. A sample of 464 women completed the Hopkins Symptom Checklist-25 and were interviewed using modules of the Structured Clinical Interview for DSM-IV. Level of psychological distress and the prevalence of psychiatric disorder were low and in the range that would be expected for a sample of community-residing women. Screening proved inefficient: Less than 10% of distressed women met criteria for a clinical disorder. High-risk women seeking genetic testing in research settings may not require extensive psychological screening and diagnostic assessment. Caution is expressed about possible self-selection biases in women enrolled in hereditary cancer registries.

Entities:  

Mesh:

Year:  2000        PMID: 11068972

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  27 in total

1.  Prospective association between distress and mammography utilization among women with a family history of breast cancer.

Authors:  Marc D Schwartz; Kathryn L Taylor; Kristen S Willard
Journal:  J Behav Med       Date:  2003-04

2.  Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns?

Authors:  Chanita Hughes Halbert; Jill E Stopfer; Jasmine McDonald; Benita Weathers; Aliya Collier; Andrea B Troxel; Susan Domchek
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

Review 3.  Specific psychosocial issues of individuals undergoing genetic counseling for cancer - a literature review.

Authors:  Willem Eijzenga; Daniela E E Hahn; Neil K Aaronson; Irma Kluijt; Eveline M A Bleiker
Journal:  J Genet Couns       Date:  2013-08-31       Impact factor: 2.537

4.  Identification of cognitive profiles among women considering BRCA1/2 testing through the utilisation of cluster analytic techniques.

Authors:  Pagona Roussi; Kerry A Sherman; Suzanne M Miller; Karen Hurley; Mary B Daly; Andrew Godwin; Joanne S Buzaglo; Kuang-Yi Wen
Journal:  Psychol Health       Date:  2011-07-14

Review 5.  Cancers related to genetic mutations: important psychosocial issues for Canadian family physicians.

Authors:  Tara E Power; John Robinson
Journal:  Can Fam Physician       Date:  2006-11       Impact factor: 3.275

6.  Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial.

Authors:  Jennifer R Klemp; Anne O'Dea; Carolyn Chamberlain; Carol J Fabian
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Factors associated with psychological distress among women of African descent at high risk for BRCA mutations.

Authors:  Yael R Cukier; Hayley S Thompson; Katarina Sussner; Andrea Forman; Lina Jandorf; Tiffany Edwards; Dana H Bovbjerg; Marc D Schwartz; Heiddis B Valdimarsdottir
Journal:  J Genet Couns       Date:  2012-06-27       Impact factor: 2.537

8.  Cognitive Behavioral Stress Management for Healthy Women at Risk for Breast Cancer: a Novel Application of a Proven Intervention.

Authors:  Bonnie A McGregor; Emily D Dolan; Karly M Murphy; Timothy S Sannes; Krista B Highland; Denise L Albano; Alison A Ward; Anna M Charbonneau; Mary W Redman; Rachel M Ceballos
Journal:  Ann Behav Med       Date:  2015-12

9.  A Counselling Model for BRCA1/2 Genetic Susceptibility Testing.

Authors:  Iris van Oostrom; Aad Tibben
Journal:  Hered Cancer Clin Pract       Date:  2004-02-15       Impact factor: 2.857

10.  Colorectal cancer in the family: psychosocial distress and social issues in the years following genetic counselling.

Authors:  Eveline M A Bleiker; Fred H Menko; Irma Kluijt; Babs G Taal; Miranda A Gerritsma; Lidwina D V Wever; Neil K Aaronson
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.